Cipla Ltd — Q2 FY26
Cipla delivered an all-time high quarterly revenue of INR 7,589 crore (+8% YoY) with a robust EBITDA margin of 25%, driven by broad-based growth across One India, US Generics, O...
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
86%Questions answered1Evaded / deflected11Questions auditedMixedNumbers vs filing
Answered
Medium priority
GLP-1: API manufacturing and fill-finish plans?
Asked by Gautam R, Leo Capital
Answered clearly about API sourcing and fill-finish arrangement.
Read the exchange
Question
For your GLP-1, do you only plan for pen finish, or do you also manufacture API and other types of finishes?
Ashish Adukia, Global CFO
We don't manufacture API ourselves. We procure it... Fill and finish right now is through CMO.
Answered
High priority
India business slowdown and tirzepatide/semaglutide plans?
Asked by Saion Mukherjee, Nomura Securities
Addressed both parts with specific commentary on recovery and launch plans.
Read the exchange
Question
If you can talk about the India business... we have seen probably some slowdown... And also, for your tirzepatide tie-up, how are you thinking about that opportunity, and are you also planning to launch semaglutide on patent expiry now?
Umang Vohra, Global MD & CEO
Yes, there is a slowdown... business is recovering strongly in quarter two... On tirzepatide, we are hoping to launch as soon as we can... On semaglutide, we will evaluate its launch into the market.
Declined
High priority
US revenue outlook and generic QVAR launch timeline?
Asked by Saion Mukherjee, Nomura Securities
Declined to answer on QVAR due to litigation; no number given for US revenue.
refused to comment on QVAR
Read the exchange
Question
If you can give a number for next quarter for the U.S. market, and also any timeline you have in mind for launch of generic QVAR now?
Umang Vohra, Global MD & CEO
Generic QVAR, I can't speak about it because it's more in the court.
Partial answer
High priority
Tirzepatide deal economics: revenue booking and profit sharing?
Asked by Damayanti Kerai, HSBC
Explained distribution rights but did not disclose revenue booking or margin split.
no specific profit-sharing details
Read the exchange
Question
Can you discuss a bit about the sort of arrangement you have? You will be booking the revenue, or how the partners will be sharing the economics?
Achin Gupta, Global COO
We will be launching a brand called Yortiq... product will be supplied by Lilly and marketed by Cipla.
Answered
High priority
Reason for wider EBITDA margin guidance and higher R&D spend?
Asked by Damayanti Kerai, HSBC
Provided multiple specific reasons for margin guidance range.
Read the exchange
Question
On your revised EBITDA margin guidance... do you anticipate much higher R&D spend than some others spend in the second half?
Ashish Adukia, Global CFO
It's not because of what you mentioned... first half had benefit of Revlimid... R&D programs picked up... quarter four is usually lowest.
Answered
Medium priority
R&D spend increase details and areas of accelerated filings?
Asked by Neha Manpuria, Bank of America
Specified therapeutic areas for R&D acceleration.
Read the exchange
Question
What would be this accelerated filing, and which specific areas are we looking at? Is this the same varenicline, respiratory, or is it biosimilar?
Ashish Adukia, Global CFO
In the similar areas as we've been working on... complex generics... respi, oligo, peptides.
Answered
High priority
India branded business growth trajectory and Eli Lilly impact?
Asked by Neha Manpuria, Bank of America
Confirmed growth trajectory without relying solely on Lilly deal.
Read the exchange
Question
How do we ensure that Cipla can go back to growing in line with the market, particularly on the branded business? Is the Eli Lilly bit that gives you confidence?
Achin Gupta, Global COO
We are building a very strong franchise on diabetes, cardio, urology... we are growing faster than market already... we will again start delivering market-beating growth.
Answered
High priority
Tirzepatide vs semaglutide opportunity post-genericization?
Asked by Surya Narayan Patra, PhillipCapital
Provided clear differentiation and market view for both molecules.
Read the exchange
Question
What is the likely scenario once genericization of semaglutide happens in India? And what is the kind of opportunity one can utilize?
Umang Vohra, Global MD & CEO
Both molecules will stand on its own... tirzepatide brings very strong and superior science... semaglutide will also be a large market.
Answered
Medium priority
Gross margin decline reason despite strong US sales?
Asked by Surya Narayan Patra, PhillipCapital
Listed specific factors for gross margin decline.
Read the exchange
Question
Sequentially, we have seen 160-170 bps decline despite strong U.S. sales. Is it because of price cut in Revlimid or something else?
Ashish Adukia, Global CFO
One reason is price decline in quarter two... tender business in Africa picked up... R&D material also hits material cost.
Evasive
Low priority
Pre-approval inspection at Kemwell facility and product tech transfer?
Asked by Shashank Krishnakumar, Emkay Global
Acknowledged but refused to disclose product details.
withheld product specifics
Read the exchange
Question
Which is the product that underwent a tech transfer to the site?
Umang Vohra, Global MD & CEO
It's a fill-finish product. We're not giving the specifics.
Answered
High priority
EBITDA margin lower in H2 despite seasonality and launches?
Asked by Tushar Manudhane, Motilal Oswal Financial Services
Explained R&D frontloading and margin impact clearly.
Read the exchange
Question
Still, you think that we'll be lower in terms of EBITDA margin compared to second quarter, even after considering the higher R&D spend?
Umang Vohra, Global MD & CEO
R&D is ramping up in the second half... we've identified a few opportunities... margin is essentially the same range.
Answered
Medium priority
Abraxane launch performance and market share?
Asked by Bino Pathiparampil, Elara Capital
Honest assessment of launch performance and current improvement.
Read the exchange
Question
How is the product picking up? Is it in line with your expectation in terms of market share, etc.?
Umang Vohra, Global MD & CEO
Not quite. We were slightly behind... market had extra stock... we are beginning to pick up share now.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| EBITDA margin guidance 22.75%-24% for FY26 | 23.375% | 25% | Understated vs filing |
| Previous EBITDA margin guidance was 23.5%-24.5% | 24% | 25% | Understated vs filing |
| First half EBITDA margin above 25% | 25% | 25% | Matches filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.